Christopher Yea
Corporate Officer/Principal bei KALVISTA PHARMACEUTICALS, INC.
Vermögen: 864 535 $ am 31.03.2024
Profil
Christopher M.
Yea was the founder who started Vantia Ltd.
in 2008, where he held the title of Chief Operating Officer until 2015.
Currently, he holds the position of Chief Development Officer at KalVista Pharmaceuticals Ltd.
since 2015 and at KalVista Pharmaceuticals, Inc. since 2016.
Dr. Yea received his undergraduate and doctorate degrees from the University of Bristol.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.02.2024 | 72 895 ( 0,17% ) | 864 535 $ | 31.03.2024 |
Aktive Positionen von Christopher Yea
| Unternehmen | Position | Beginn |
|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.11.2016 |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Corporate Officer/Principal | 01.11.2015 |
Ehemalige bekannte Positionen von Christopher Yea
| Unternehmen | Position | Ende |
|---|---|---|
Vantia Ltd.
 Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Founder | 01.11.2015 |
Ausbildung von Christopher Yea
| University of Bristol | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
